The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring
Abstract
Cytochrome P450 (CYP) 3A4 is the most abundant enzyme of CYPs in the liver and gut that metabolizes approximately 50% currently available drugs. A number of important drugs have been identified as substrates, inducers, and/or inhibitors of CYP3A4. The substrates of CYP3A4 considerably overlap with those of P-glycoprotein. Both CYP3A4 and P-glycoprotein are subject to inhibition and induction by a number of factors. Mechanism-based inhibition of CYP3A4 is characterized by NADPH-, time-, and concentration-dependent enzyme inactivation occurring when some xenobiotics or drugs are converted by CYPs to reactive metabolites. Such an inhibition of CYP3A4 is caused by chemical modification of the heme, the protein, or both as a result of covalent binding of modified heme to the protein. To date, the identified clinically important mechanism-based CYP3A4 inhibitors mainly include macrolide antibiotics (eg, clarithromycin and erythromycin), anti-HIV agents (eg, ritonavir and delavirdine), antidepressants (eg, fluoxetine and fluvoxamine), calcium channel blockers (eg, verapamil and diltiazem), steroids and their modulators (eg, gestodene and mifepristone), and several herbal and dietary components. The inactivation of CYP3A4 by drugs often causes unfavorable and long-lasting drug-drug interactions and probably fatal toxicity, depending on many factors associated with the enzyme, drugs, and the patients. Clinicians are encouraged to have a sound knowledge of drug-induced, mechanism-based CYP3A4 inhibition; take proper cautions, and perform close monitoring for possible drug interactions when using drugs that are mechanism-based CYP3A4 inhibitors. To minimize drug-drug interactions involving mechanism-based CYP3A4 inhibition, it is necessary to choose safe drug combination regimens, adjust drug dosages appropriately, and conduct therapeutic drug monitoring for drugs with narrow therapeutic indices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
The pharmacology and clinical uses of tamoxifen
Furr, B. J. A., & Jordan, V. C. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90043-3 · Cited by 864
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
Huang, S.-M., Temple, R., Throckmorton, D. C., & Lesko, L. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100054 · Cited by 579
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Self-citationIto, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
Obach, R. S., Walsky, R. L., & Venkatakrishnan, K. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012633 · Cited by 460
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
Pichard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G., & Maurel, P. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08600-3 · Cited by 433
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Patten, C. J., Thomas, P. E., Guy, R. L., Lee, M., Gonzalez, F. J., Guengerich, F. P., & Yang, C. S. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00034a019 · Cited by 417
Drugs as P-glycoprotein substrates, inhibitors, and inducers
Kim, R. B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001389 · Cited by 382
Honig, P. K., Woosley, R. L., Zamani, K., Conner, D. P., & Cantilena, L. R. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.135 · Cited by 367
Yusa, K., & TSURUO, T. (1989) · PubMed · Cited by 365
Pharmacokinetic Drug Interactions of Macrolides
Periti, P., Mazzei, T., Mini, E., & Novelli, A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223020-00004 · Cited by 358
Hollenberg, P. F., Edwards, D. J., He, K., Fitzsimmons, M. E., Fisher, J. M., Rahman, A., Thummel, K. E., Lown, K. S., Woster, P. M., Schmiedlin‐Ren, P., et al. (2019) · PubMed · doi:10.17615/k2j5-jx75 · Cited by 349
Yuan, R., Madani, S., Wei, X.-X., Reynolds, K., & Huang, S.-M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1311 · Cited by 325
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
He, K., Iyer, K. R., Hayes, R. N., Sinz, M., Woolf, T. F., & Hollenberg, P. F. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970192k · Cited by 312
Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 286
Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
Guengerich, F. P. (1990) · Chemical Research in Toxicology · doi:10.1021/tx00016a015 · Cited by 279
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Self-citationKoudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E. T., Vouros, P., Storozhuk, E., Orza, D., Marinina, J., & Gerber, N. (1998) · PubMed · Cited by 259
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors
Ernest, C. S., Hall, S. D., & Jones, D. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075416 · Cited by 246
Tamoxifen (‘Nolvadex’): a review
Clemons, M., Danson, S., & Howell, A. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00036-1 · Cited by 229
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00487.x · Cited by 225
Macrolide Antibacterials: Drug Interactions of Clinical Significance
von Rosenstiel, N.-A., & Adam, D. (1995) · Drug Safety · doi:10.2165/00002018-199513020-00005 · Cited by 212
SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES
Sridar, C., Goosen, T. C., Kent, U. M., Williams, J. A., & Hollenberg, P. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.587 · Cited by 192
Cytochrome P450 Isozymes and Antiepileptic Drug Interactions
Levy, R. H. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb06007.x · Cited by 187
Eagling, Profit, & Back (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00052.x · Cited by 179
Ma, B., Prueksaritanont, T., & Lin, J. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15118-5 · Cited by 176
The interaction of diltiazem with lovastatin and pravastatin*
Azie, N. E., Brater, D. C., Becker, P. A., Jones, D. R., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90067-4 · Cited by 174
Jurima-Romet, M., Crawford, K., Cyr, T., & Inaba, T. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08427-2 · Cited by 163
Galetin, A., Burt, H., Gibbons, L., & Houston, J. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006874 · Cited by 160
Wen, X., Wang, J., Neuvonen, P. J., & Backman, J. T. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0396-3 · Cited by 157
Mikus, G., SCHOWEL, V., Drzewinska, M., Rengelshausen, J., DING, R., RIEDEL, K., Burhenne, J., WEISS, J., Thomsen, T., & Haefeli, W. E. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.004 · Cited by 157
Mullins, M. E., Horowitz, B. Z., Linden, D. H., Smith, G. W., Norton, R. L., & Stump, J. (1998) · JAMA · doi:10.1001/jama.280.2.157 · Cited by 156
Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Zhou, S., Chan, E., Lim, L. Y., Boelsterli, U. A., Li, S., Wang, J., Zhang, Q., Huang, M., & Xu, A. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335450 · Cited by 155
Self-citationKalgutkar, A. S. S., Vaz, A. D. N., Lame, M. E., Henne, K. R., Soglia, J. R., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C., Hendsch, Z. S., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001735 · Cited by 155
Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., et al. (2002) · Chemical Research in Toxicology · doi:10.1021/tx0200109 · Cited by 154
IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACT
Iwata, H., Tezuka, Y., Kadota, S., Hiratsuka, A., & Watabe, T. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000646 · Cited by 153
Khan, K. K., He, Y., Domanski, T. L., & Halpert, J. R. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12112-8 · Cited by 152
Kent, U. M., Aviram, M., Rosenblat, M., & Hollenberg, P. F. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.709 · Cited by 152
Ito, K., Ogihara, K., Kanamitsu, S.-I., & Itoh, T. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.945 · Cited by 151
Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4
Chan, W. K., & Delucchi, A. B. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00888-2 · Cited by 150
Rawden, H. C., Kokwaro, G. O., Ward, S. A., &, & Edwards, G. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00170.x · Cited by 146
Drug Interactions of HIV Protease Inhibitors
Malaty, L. I., & Kuper, J. J. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00005 · Cited by 146
Chatterjee, P., & Franklin, M. R. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1391 · Cited by 146
Jones, D. R., Gorski, J. C., Hamman, M. A., Mayhew, B. S., Rider, S., & Hall, S. D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35013-x · Cited by 145
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang, L., Wring, S. A., Woolley, J. L., Brouwer, K. R., Serabjit‐Singh, C. J., & Polli, J. W. (2001) · PubMed · Cited by 142
O'Regan, R. M., & Jordan, V. C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00711-8 · Cited by 142
Pharmacokinetic Interactions of the Macrolide Antibiotics
Ludden, T. M. (1985) · Clinical Pharmacokinetics · doi:10.2165/00003088-198510010-00003 · Cited by 140
Metabolism of 17 α-ethynylestradiol in humans
Guengerich, F. P. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90431-p · Cited by 139
Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers
Piscitelli, S. C., Formentini, E., Burstein, A. H., Alfaro, R. M., Jagannatha, S., & Falloon, J. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.8.551.33205 · Cited by 138
ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO
Perloff, E. S., Duan, S. X., Skolnik, P. R., Greenblatt, D. J., & Moltke, L. L. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002931 · Cited by 134
Lin, H.-L., Kent, U. M., & Hollenberg, P. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.160 · Cited by 132
Butler, A. M., & Murray, M. T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36464-x · Cited by 131
Alprazolam-ritonavir interaction: Implications for product labeling
Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Durol, A. L., Daily, J. P., Graf, J. A., Mertzanis, P., Hoffman, J. L., & Shader, R. I. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.105757 · Cited by 128
Drug Interactions with Cisapride
Michalets, E. L., & Williams, C. R. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039010-00004 · Cited by 126
An Update and Review of Antiretroviral Therapy
Piacenti, F. J. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.8.1111 · Cited by 126
Loo, T. W., & Clarke, D. M. (1994) · Biochemistry · doi:10.1021/bi00251a013 · Cited by 123
Functional interaction of intestinal CYP3A4 and P‐glycoprotein
Kivistö, K. T., Niemi, M., & Fromm, M. F. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00291.x · Cited by 120
Rhabdomyolysis due to interaction of simvastatin with mibefradil
Schmassmann-Suhijar, D., Bullingham, R. E. S., Gasser, R., Schmutz, J., & Haefeli, W. E. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78613-x · Cited by 118
Dual effects of macrolide antibiotics on rat liver cytochrome P-450
Delaforge, M., Jaouen, M., & Mansuy, D. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90178-8 · Cited by 116
Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
Yamazaki, H., & Shimada, T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00304-3 · Cited by 113
Bensoussan, C., Delaforge, M., & Mansuy, D. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00477-4 · Cited by 110
Aryl Acetylenes as Mechanism-Based Inhibitors of Cytochrome P450-Dependent Monooxygenase Enzymes
Foroozesh, M. K., Primrose, G., Guo, Z., Bell, L. C., Alworth, W. L., & Guengerich, F. P. (1997) · Chemical Research in Toxicology · doi:10.1021/tx960064g · Cited by 108
Lillibridge, J. H., Liang, B. H., Kerr, B. M., Webber, S., Quart, B. D., Shetty, B. V., & Lee, C. A. (1998) · PubMed · Cited by 106
Effects of erythromycin on hepatic drug-metabolizing enzymes in humans
Larrey, D. G., Funck‐Brentano, C., Breil, P., Vitaux, J., Theodore, C., Babany, G., & Pessayre, D. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90626-3 · Cited by 104
Prueksaritanont, T., Ma, B., Tang, C., Meng, Y., Assang, C., Lü, P., Reider, P. J., Lin, J. H., & Baillie, T. A. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00903.x · Cited by 102
Plant, N. J. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.09.024 · Cited by 99
Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro
Polasek, T. M., Elliot, D. J., Lewis, B. C., & Miners, J. O. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071803 · Cited by 96
Kanamitsu, S.-I., Ito, K., Green, C. E., Tyson, C. A., Shimada, N., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007572803027 · Cited by 94
Effect of tadalafil on cytochrome P450 3A4?mediated clearance: Studies in vitro and in vivo
Ring, B. J., Patterson, B. E., MITCHELL, M., VandenBranden, M. R., Gillespie, J. S., Bedding, A. W., Jewell, H., PAYNE, C., Forgue, S. T., Eckstein, J. A., et al. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.09.006 · Cited by 92
Clinical Importance of the Interaction of Phenytoin and Isoniazid
Miller, R. R., Porter, J., & Greenblatt, D. J. (1979) · CHEST Journal · doi:10.1378/chest.75.3.356 · Cited by 89
Amacher, D. E., Schomaker, S., & Retsema, J. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1186 · Cited by 87
Nolan, C. M., Sandblom, R. E., Thummel, K. E., Slattery, J. T., & Nelson, S. D. (1994) · CHEST Journal · doi:10.1378/chest.105.2.408 · Cited by 86
von Moltke, L. L., Durol, A. L. B., Duan, S. X., & Greenblatt, D. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000125 · Cited by 85
Baer, B. R., Wienkers, L. C., & Rock, D. A. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700037e · Cited by 84
DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL
Wang, Y.-H., Jones, D. R., & Hall, S. D. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001834 · Cited by 84
Lim, H., Duczak, N., Brougham, L. R., Elliot, M., Patel, K., & Chan, K. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003475 · Cited by 84
Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes
Yeo, K. R., & Yeo, W. W. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01386.x · Cited by 83
Polasek, T. M., & Miners, J. O. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0091-x · Cited by 83
Clinical Pharmacokinetics of Mibefradil
Welker, H. A., WILTSHIRE, H. R., & Bullingham, R. E. S. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835060-00001 · Cited by 83
Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides.
Tinel, M., Descatoire, V., Larrey, D. G., Loeper, J., Labbe, G., Lettéron, P., & Pessayre, D. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22274-1 · Cited by 82
Isoniazid Drug and Food Interactions
Self, T. H., Chrisman, C. R., Baciewicz, A. M., & Bronze, M. S. (1999) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40533-6 · Cited by 82
Yamano, K., Yamamoto, K., Katashima, M., Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y., & Iga, T. (2001) · PubMed · Cited by 80
EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES
Zhao, P., Kunze, K. L., & Lee, C. A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002832 · Cited by 78
Kurnik, D., Wood, A., & Wilkinson, G. R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.002 · Cited by 76
Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., D'Amico, R. D., Mildvan, D., Gulick, R. M., Hughes, V., Flexner, C. W., Aweeka, F. T., et al. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200106010-00010 · Cited by 73
In Vitro Evaluation of the Disposition of A Novel Cysteine Protease Inhibitor
Jacobsen, W., Christians, U., & Benet, L. Z. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15083-0 · Cited by 71
Diclofenac-Induced Inactivation of CYP3A4 and Its Stimulation by Quinidine
Masubuchi, Y., Ose, A., & Horie, T. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1143 · Cited by 70
Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites
Zhao, X.-J., Jones, D. R., Wang, Y.-H., et al. (2002) · Xenobiotica · doi:10.1080/00498250210158230 · Cited by 67
Komatsu, T., Yamazaki, H., Asahi, S., Gillam, E. M. J., Guengerich, F. P., Nakajima, M., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15085-4 · Cited by 67
Lu, C., Miwa, G. T., Prakash, S. R., Gan, L.-S. L., & Balani, S. K. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011346 · Cited by 66
Acetaminophen hepatotoxicity: potentiation by isoniazid.
Crippin, J. S. (1993) · PubMed · Cited by 64
Rhabdomyolysis due to probable interaction between simvastatin and ritonavir
Cheng, C. H., Miller, C., Lowe, C., & Pearson, V. E. (2002) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/59.8.728 · Cited by 63
Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5)
Jones, D. R., Ekins, S., Li, L., & Hall, S. D. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014613 · Cited by 60
Systematic Overview of Drug Interactions with Antidepressant Medications
Nieuwstraten, C., Labiris, N. R., & Holbrook, A. M. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100506 · Cited by 57
Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.
Pessayre, D., Tinel, M., Larrey, D. G., Cobert, B., Funck‐Brentano, C., & Babany, G. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33535-4 · Cited by 53
Kalgutkar, A. S. S., Henne, K. R., Lame, M. E., Vaz, A. D. N., Collin, C., Soglia, J. R., Zhao, S. X., & Hop, C. E. C. A. (2005) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.03.036 · Cited by 53
Venkatakrishnan, K., Moltke, L. L., Duan, S. X., Fleishaker, J. C., Shader, R. I., & Greenblatt, D. J. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb06859.x · Cited by 48
Masubuchi, Y., & Horie, T. (1999) · Chemical Research in Toxicology · doi:10.1021/tx9901276 · Cited by 46
Potential Interaction Involving Warfarin and Ritonavir
Knoell, K. R., Young, T. M., & Cousins, E. S. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17456 · Cited by 43
Mechanism-Based Inactivation of Cytochrome P450 3A4 by L-754,394
Lightning, L. K., Jones, J. P., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., & Trager, W. F. (2000) · Biochemistry · doi:10.1021/bi992412u · Cited by 42
Mechanism-Based Inactivation of Cytochrome P450 3A4 by 4-Ipomeanol
Alvarez-Diez, T. M., & Zheng, J. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034143l · Cited by 40
CARDIOVASCULAR DRUG-DRUG INTERACTIONS
Anderson, J. R., & Nawarskas, J. J. (2001) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70209-5 · Cited by 36
Booker, B. M., Magee, M. H., Blum, R. A., Lates, C. D., & Jusko, W. J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127944 · Cited by 35
Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease
Simonsen, U. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900846 · Cited by 31
Antidepressant Drug-Drug Interaction Profile Update
Ereshefsky, L., Jhee, S. S., & Grothe, D. R. (2005) · Drugs in R&D · doi:10.2165/00126839-200506060-00002 · Cited by 30
Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., D'Amico, R. D., Mildvan, D., Gulick, R. M., Hughes, V., Flexner, C. W., Aweeka, F. T., et al. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200106010-00010 · Cited by 28
Calcium channel blockers in cardiac failure
Mahon, N., & McKenna, W. J. (1998) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(98)80055-8 · Cited by 27
Update on clinical role of tamoxifen
Benson, J. R., & Pitsinis, V. (2003) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200302000-00003 · Cited by 20
Further elucidation of pharmacokinetic interaction between diltiazem and warfarin.
Stoysich, A. M., Bd, L., Mohiuddin, S. M., & Hilleman, D. E. (1996) · PubMed · Cited by 14
Cited by
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
Smith, H. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60750-7 · Cited by 696
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
Zhou, S.-F. (2008) · Xenobiotica · doi:10.1080/00498250701867889 · Cited by 599
Self-citationAntiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Grimm, S. W., Einolf, H. J., Hall, S. D., He, K., Lim, H.-K., Ling, K.-H. J., Lu, C., Nomeir, A. A., Seibert, E., Skordos, K. W., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026716 · Cited by 310
Metadata
- Authors
- Zhou, S.-F., Xue, C. C., Yu, X.-Q., Li, C., & Wang, G.
- Venue
- Therapeutic Drug Monitoring
- Published
- 2007-12
- Volume
- 29
- Issue
- 6
- Pages
- 687-710
- ISSN
- 0163-4356 (ISSN-L)
- OpenAlex
- W1994904603
- Cited by
- 375
- References
- 122
- FWCI
- 19.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.